Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pliant Therapeutics ( (PLRX) ) just unveiled an update.
On March 12, 2025, Pliant Therapeutics’ board of directors adopted a stockholder rights agreement to protect against hostile takeovers by issuing a dividend of one preferred share purchase right for each outstanding share of common stock. This move aims to prevent any entity from gaining control of the company without paying a control premium, ensuring that the board has the opportunity to act in the best interests of all stockholders. The rights become exercisable if a person or group acquires 10% or more of the company’s common stock without board approval, allowing existing stockholders to purchase additional shares at a discount, thus diluting the acquiring party’s stake.
More about Pliant Therapeutics
Pliant Therapeutics is a late-stage biopharmaceutical company focused on developing novel therapeutics for fibrotic diseases. Its lead product candidate, bexotegrast, is an oral small molecule in development for idiopathic pulmonary fibrosis and has received Fast Track and Orphan Drug Designations from the FDA and Orphan Drug Designation from the European Medicines Agency.
YTD Price Performance: -88.10%
Average Trading Volume: 2,440,128
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $95.83M
For detailed information about PLRX stock, go to TipRanks’ Stock Analysis page.